A brief overlap of ruxolitinib and Ropeg-IFNa in one MPN-U patient illustrates a potentially complementary strategy: rapid symptomatic and splenic control from JAK2 inhibition plus interferon’s disease-modifying effect. This evidence concerns the gene JAK2 and myeloproliferative disorder.